Stocksigma LogoStocksigma Logo

Mankind Pharma Reports Strong Q2 FY27 With PAT Up 37.7% YoY

Mankind Pharma reported a 17.3% YoY rise in consolidated revenue to INR 4,338 Cr for Q2 FY27, supported by a 14.8% increase in domestic revenue to INR

Mankind Pharma Reports Strong Q2 FY27 With PAT Up 37.7% YoY

Mankind Pharma Ltd 路 Press Release 路 26 Oct 2026, 8:56 pm

Mankind Pharma Reports Strong Q2 FY27 With PAT Up 37.7% YoY Mankind Pharma reported a 17.3% YoY rise in consolidated revenue to INR 4,338 Cr for Q2 FY27, supported by a 14.8% increase in domestic revenue to INR 3,657 Cr and a 32.7% surge in exports to INR 681 Cr. EBITDA grew 27.2% YoY to INR 1,175 Cr with margins expanding 210 bps to 27.1%, while PAT jumped 37.7% YoY to INR 716 Cr. H1 FY27 revenue reached INR 8,368 Cr, up 15.1% YoY, with PAT at INR 1,290 Cr. Growth was driven by outperformance in chronic and acute domestic portfolios.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements